Reuters logo
6 months ago
BRIEF-Ziopharm says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma
January 11, 2017 / 4:05 PM / 6 months ago

BRIEF-Ziopharm says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma

1 Min Read

Jan 11 (Reuters) - Ziopharm Oncology Inc :

* Ziopharm Oncology says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma - Sec Filing

* Ziopharm Oncology inc says determine design of pivotal trial for recurrent Glioblastoma to be initiated in 2017 Source text (bit.ly/2iG4l9W) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below